In the first study in 2013, there were 55 and 46 women evaluable at 12 and 24 months after the breast cancer diagnosis, respectively, and the authors found an AUC for pretreatment AMH of 0.90 (95% CI 0.82–0.97), and for age, 0.88 (95% CI 0.78–0.97). This evidence concerns the gene AMH and breast carcinoma.